Cargando…
Virologic Tools for HCV Drug Resistance Testing
Recent advances in molecular biology have led to the development of new antiviral drugs that target specific steps of the Hepatitis C Virus (HCV) lifecycle. These drugs, collectively termed direct-acting antivirals (DAAs), include non-structural (NS) HCV protein inhibitors, NS3/4A protease inhibitor...
Autores principales: | Fourati, Slim, Pawlotsky, Jean-Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690865/ https://www.ncbi.nlm.nih.gov/pubmed/26690198 http://dx.doi.org/10.3390/v7122941 |
Ejemplares similares
-
Hepatitis C Virus Serologic and Virologic Tests and Clinical Diagnosis of HCV-Related Liver Disease
por: Chevaliez, Stéphane, et al.
Publicado: (2006) -
Recent advances in understanding and diagnosing hepatitis B virus infection
por: Fourati, Slim, et al.
Publicado: (2016) -
Approaches for simplified HCV diagnostic algorithms
por: Fourati, Slim, et al.
Publicado: (2018) -
Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice
por: Chevaliez, Stéphane, et al.
Publicado: (2009) -
SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients
por: Fourati, Slim, et al.
Publicado: (2020)